scholarly journals Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding

2013 ◽  
Vol 54 (12) ◽  
pp. 3345-3357 ◽  
Author(s):  
Hong-mei Gu ◽  
Ayinuer Adijiang ◽  
Matthew Mah ◽  
Da-wei Zhang
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Lipoprotein Receptor ◽  
Low Density Lipoprotein Receptor ◽  
Density Lipoprotein Receptor

scholarly journals Original research Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania

2010 ◽  
Vol 2 ◽  
pp. 198-200 ◽  
Author(s):  
Maria Diakou ◽  
George Miltiadous ◽  
Stavroula Xenophontos ◽  
Marios Cariolou ◽  
Nevila Heta ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Gene Mutations ◽  
Density Lipoprotein ◽  
Original Research ◽  
Low Density ◽  
Lipoprotein Receptor ◽  
Ldlr Gene ◽  
Low Density Lipoprotein Receptor ◽  
Density Lipoprotein Receptor

scholarly journals Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity

2022 ◽  
Vol 8 ◽  
Author(s):  
Chiara Macchi ◽  
Maria Francesca Greco ◽  
Chiara Favero ◽  
Laura Dioni ◽  
Laura Cantone ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Present Report ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Lipoprotein Receptor ◽  
Low Density Lipoprotein Receptor ◽  
Density Lipoprotein Receptor ◽  
Mirna Content

Background: Extracellular vesicles (EV) concentration is generally increased in patients with cardiovascular diseases, although the protective role of EVs in atherosclerosis has been reported. Among the specific cargo of EVs, miRNAs contribute to different stages of atherosclerosis. Aim of the present report has been to investigate, in individuals with obesity, the interplay among EVs derived from cells relevant for the atherosclerotic process (i.e., platelets, endothelium, monocytes/macrophages, and neutrophils), their miRNA content and proprotein convertase subtilisin/kexin type 9 (PCSK9), one of the main regulators of low-density lipoprotein receptor (LDLR).Methods and Results: EVs have been isolated from 936 individuals with obesity (body mass index = 33.6 ± 5.6 Kg/m2) and a raised cardiovascular risk (e.g., LDL-C = 131.6 ± 36.4 mg/dL, HOMA-IR = 3.1, and roughly 50% on anti-hypertensive medications). PCSK9 levels were negatively associated with EV count in the range 150–400 nm and with those derived from macrophages (CD14+), endothelium (CD105+), and neutrophils (CD66+). The association between PCSK9 and platelet-derived EVs (CD61+) was modified by platelet counts. PCSK9 was significantly associated with five EV-derived miRNAs (hsa-miRNA−362−5p,−150,−1244,−520b-3p,−638). Toll-like receptor 4 and estrogen receptor 1 were targeted by all five miRNAs and LDLR by four. The effect on LDLR expression is mainly driven by hsa-miR-150. Considering the implication of EV in atherosclerosis onset and progression, our findings show a potential role of PCSK9 to regulate EV-derived miRNAs, especially those involved in inflammation and expression of low-density lipoprotein receptor (LDLR) receptor.

Sign in / Sign up

Export Citation Format

Share Document